We have established a portfolio of proprietary product development programs that includes both biologics and pharmaceuticals. Our most advanced programs are in the area of regenerative medicine, applying our patented and proprietary stem cell product, MultiStem®, that we believe has potential for treating multiple disease conditions, including in the neurological, cardiovascular, inflammatory and immune disease areas. Over the past several years, we have advanced MultiStem programs to clinical development stage and established preclinical programs through our internal efforts and broad network of collaborations across the United States and Europe. We believe that our pipeline can be broadened over time, driven by our technologies, capabilities and approach. In addition to our programs in regenerative medicine, we are also applying our other technologies and capabilities to develop new pharmaceutical based treatments for obesity, related metabolic conditions and certain neurological disorders.
In collaboration with leading stroke treatment centers in the U.S. and the United Kingdom, we recently reported initial results from a double blind, placebo controlled Phase 2 clinical trial evaluating the safety and efficacy of MultiStem® administered intravenously to ischemic stroke victims.